Market closed

IGM Biosciences/$IGMS

14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX

About IGM Biosciences

IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.

Ticker

$IGMS
Sector
Health Care
Trading on
NASDAQ

Industry

Biotechnology
Headquarters
Mountain View, United States

Employees

198
Website
igmbio.com

IGM Biosciences Metrics

BasicAdvanced
$106M
-
-$3.65
0.01
-

$106M

0.01

$17.70

$1.77

455K

5.223

4.999

49.605

58.086

-37.38%

-132.11%

36.668

1.34

1.34

-0.62

57.64%

-25.92%

-4.86%

What the Analysts think about IGM Biosciences

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for IGM Biosciences stock.

IGM Biosciences Financial Performance

Income Statement

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

IGM Biosciences Earnings Performance

Earnings per share (EPS)

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-

IGM Biosciences News

AllArticlesVideos
IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out

IGM Biosciences to cut 73% of workforce as latest pivot fails to pan out

Market Watch·6 days ago
IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

IGM Biosciences Provides Strategic Update on Autoimmunity Pipeline Programs

GlobeNewsWire·6 days ago
IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

IGM Biosciences Announces Third Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewsWire·2 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $IGMS

$

Sign up or log in to buy
Capital at risk
Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for IGM Biosciences stock?

IGM Biosciences (IGMS) has a market cap of $106M as of January 15, 2025.

What is the P/E ratio for IGM Biosciences stock?

The price to earnings (P/E) ratio for IGM Biosciences (IGMS) stock is 0 as of January 15, 2025.

Does IGM Biosciences stock pay dividends?

No, IGM Biosciences (IGMS) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next IGM Biosciences dividend payment date?

IGM Biosciences (IGMS) stock does not pay dividends to its shareholders.

What is the beta indicator for IGM Biosciences?

IGM Biosciences (IGMS) has a beta rating of 0.01. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.